ArticleInternational journal of molecular sciences2019
Chromogranin-A Expression as a Novel Biomarker for Early Diagnosis of Colon Cancer Patients.
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 62 citations in OpenAlex.
- Integrated bioinformatics and experimental validation reveal that CENPF activates mTORC1 signaling to promote colorectal cancer progression.Cancer cell international · 2026Article
- Expression of ubiquitin carboxyl-terminal hydrolase isozyme L1 and chromogranin A regulated via histone-modification through Rho/ERK/NFκB signaling in oxaliplatin-resistant colorectal cancer cells.International journal of medical sciences · 2026Article
- Downregulation of Enteroendocrine Genes Predicts Survival in Colon Cancer: A Bioinformatics-Based Analysis.International journal of molecular sciences · 2025Article
- Article
- RBM5 suppresses proliferation, metastasis and glycolysis of colorectal cancer cellsWorld journal of gastrointestinal oncology · 2024Article
- Immune-related signature identifies IL1R2 as an immunological and prognostic biomarker in pancreatic cancer.Journal of pancreatology · 2024Article
- Single-cell transcriptomics reveals stage- and side-specificity of gene modules in colorectal cancer.Research square · 2024Article
- Holistic exploration ofHeliyon · 2024Article
- ULBP2 is a biomarker related to prognosis and immunity in colon cancer.Molecular and cellular biochemistry · 2023Article
- Use of iTRAQ-based quantitative proteomic identification of CHGA and UCHL1 correlated with lymph node metastasis in colorectal carcinoma.Journal of cellular and molecular medicine · 2023Article
- Antibody-Loaded Nanoplatforms for Colorectal Cancer Diagnosis and Treatment: An Update.Pharmaceutics · 2023Review
- Constructed the ceRNA network and predicted a FEZF1-AS1/miR-92b-3p/ZIC5 axis in colon cancer.Molecular and cellular biochemistry · 2023Article
- Single-cell transcriptomic analysis of normal and pathological tissues from the same patient uncovers colon cancer progression.Cell & bioscience · 2023Article
- MetaProD: A Highly-Configurable Mass Spectrometry Analyzer for Multiplexed Proteomic and Metaproteomic Data.Journal of proteome research · 2023Article
- Non-Canonical Programmed Cell Death in Colon Cancer.Cancers · 2022Review
- Article
- A novel hypoxia-driven gene signature that can predict the prognosis of hepatocellular carcinoma.Bioengineered · 2022Article
- NOX4 has the potential to be a biomarker associated with colon cancer ferroptosis and immune infiltration based on bioinformatics analysis.Frontiers in oncology · 2022Article
- Anticolon Cancer Targets and Molecular Mechanisms of Tao-He-Cheng-Qi Formula.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Identification and validation of an immune-related gene prognostic signature for clear cell renal carcinoma.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Colon cancer is one of the major causes of cancer death worldwide. The five-year survival rate for the early-stage patients is more than 90%, and only around 10% for the later stages. Moreover, half of the colon cancer patients have been clinically diagnosed at the later stages. It is; therefore, of importance to enhance the ability for the early diagnosis of colon cancer. Taking advantages from our previous studies, there are several potential biomarkers which have been associated with the early diagnosis of the colon cancer. In order to investigate these early diagnostic biomarkers for colon cancer, human chromogranin-A (CHGA) was further analyzed among the most powerful diagnostic biomarkers. In this study, we used a logistic regression-based meta-analysis to clarify associations of CHGA expression with colon cancer diagnosis. Both healthy populations and the normal mucosa from the colon cancer patients were selected as the double normal controls. The results showed decreased expression of CHGA in the early stages of colon cancer as compared to the normal controls. The decline of CHGA expression in the early stages of colon cancer is probably a new diagnostic biomarker for colon cancer diagnosis with high predicting possibility and verification performance. We have also compared the diagnostic powers of CHGA expression with the typical oncogene KRAS, classic tumor suppressor TP53, and well-known cellular proliferation index MKI67, and the CHGA showed stronger ability to predict early diagnosis for colon cancer than these other cancer biomarkers. In the protein-protein interaction (PPI) network, CHGA was revealed to share some common pathways with KRAS and TP53. CHGA might be considered as a novel, promising, and powerful biomarker for early diagnosis of colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.